Head of the Thoracic Oncology Unit
@utoracica
and the Personalized Medicine Lab, Instituto Nacional de Cancerología 🇲🇽
@incanmx
, Medicine Professor
@UNAM_MX
Tocilizumab decreased the risk of intubation or death in COVID-19 in a Spanish RETROSPECTIVE study (0.32, p <0.001) in patients with elevated ferritin, dd or IL-6, Suggesting that the selection of patient in future clinical studies it should be based on the state of inflammation
Our randomized, double-blind, placebo-controlled
clinical trial recently published in
@JAMAOnc
shows that mirtazapine compared to placebo improves energy and oral intake including proteins, carbohydrates and fats in NSCLC patients. The mirtazapine group decreased sarcopenia
Prophylactic Cranial Irradiation has not been evaluated in advanced NSCLC patients at high risk for brain metastases. We conducted a randomized study where we showed that PCI was associated with a reduction to develop BM (0.12 [0.035-0.42], particularly in mEGFR and ALK
@incanMX
Approximately 65% of lung adenocarcinomas elevate the carcinomebrionic antigen. The reduction of more than 20% of CEA levels with chemotherapy or EGFR TKI is strongly associated with an improvement in survival. This is shown by our study recently published in clinical lung cancer
Our study demonstrated that increased perilesional edema (PE) from brain metastases (BM) from NSCLC is a negative predictor of response to radiation therapy, short intracranial-PFS, and even worse OS. The PE should be evaluated to be integrated into the BM prognostic scales.
Clausura del año académico
@ANacionalMed
. La doctora Patrícia Volkow es reconocida con la mejor trayectoria científica a las mujeres en medicina, miembro del
@incanMX
@dvilarc
Hoy iniciamos el curso "Implementación de registros de cáncer de base poblacional" avalado por la
@UNAMmx
y la
@FacMedicinaUNAM
, un paso más en el fortalecimiento del registro en nuestro país y un trabajo de colaboración entre
@Tu_IMSS
@SSalud_mx
@incanMX
con el liderazgo de
Due to the COVID-19 pandemic, a significant delay in the diagnosis and treatment of cancer has been observed, this will generate a reduction in the expectation of survival. Shown here reduction in net 10-year survival incurred by a 3-month delay for the 20 most common tumors.
En el
@incan
99.2% de todos los casos de cáncer de pulmón son diagnosticados en etapas avanzadas (III y IV) con menor posibilidad de curación y un costo de atención 10 veces superior que las etapas tempranas. Por eso iniciamos el programa de tamizaje
@detectoincan
en el Instituto
Most lung cancer screening programs primarily target subjects with a history of smoking as the leading risk factor. Our recently published review discusses risk prediction models to optimize screening in non-smokers to accurately identify individuals who should be included in
Lack of access to innovative treatments dramatically affects survival. Greater access to immunotherapy treatment is necessary for patients with renal cell cancer. Great collaborative work of Mexican oncologists led by
@BourlonMaite
and Dra. Nora sobrevilla. Congratulations for
El protocolo de tamizaje de cáncer de pulmón DETECTO, primer programa para la detección temprana de cáncer de pulmón en 🇲🇽
@detectoincan
del
@incanMX
y de
@UToracica
, se expande a diferentes ciudades de la República 🇲🇽, en colaboración con
@SMNYCT
, con el fin de generar
Felicidades a la Dra paula Cabrera,
@anelcabrera
vice presidente de la
@SMEOMX
y subdirectora de oncología y hematologia del
@incanMX
, excepcional mujer, doctora, científica
More than 20 years ago, we identified a family with hereditary gastric cancer in
@incmnszmx
We sent the samples to experts in hereditary cancer to perform genetic tests for CDH1 and CTNNA, which were initially negative.
@SaoJoseCelina
@josegp_92
@CaldasLab
@incanMX
In this study we developed a survival score for patients with brain metastases that have required irradiation BIR based on age (50y), primary tumor control, size (20mm) and PFS interval at first irradiation (12m). this score could help in making decisions to offer BIR treatment
Multidisciplinary team of the Lung Cancer Clinic,
@incanMX
. Early detection, rehabilitation, radiotherapy, surgery, pulmonology, nursing, nutrition, fellows of thoracic oncology, precision medicine lab, PhD students, smoking cessation and medical oncology. INCan 75th anniversary
Muchas gracias a todos los ponentes, coordinadores y asistentes del curso lo mejor de cancer de Pulmon del 2022, mas de 200 trabajos presentados incluyendo investigacion de España 🇪🇸 y Latam y mas de 2000 inscritos
@fcounago
@AndresFCardonaZ
@MARIANOPROVENCI
@CLICaP_
@gecp_org
El vapeador, una amenaza contra las medidas anti tabaquismo, el día de hoy presentamos el libro del dr Juan Zinser, médico del
@incanMX
del cigarro al vapeador,
@MarisolNeumo
@UToracica
El Día de hoy, arrancamos con la actualización o creación de nuevos protocolos de atención medica de las neoplasias malignas en pediatría y hematología coordinadas por el
@DeSalubridad
y representación de muchas instituciones como
@CCINSHAE_mx
@Tu_IMSS
@SSaludCdMx
@ISSSTE_mx
,
Although the main cause of lung cancer is smoking there are other risk factors, only lung cancer not associated with smoking would be the sixth leading cause of cancer death in the world
Impact of KRAS G12D and concurrent mutations on NSCLC outcomes. Our cohort shows 15.6% mKRAS (32, 32, 14% for G12C, G12D and G12V), G12D is associated with female and a lower smoking rate (pack/year).
@incanMX
@AndresFCardonaZ
@Ecaballep
We´re very excited to share this collaborative effort by thoracic cancer experts from around the world. We gathered evidence and voted in a series of recommendations to implement in case of limited resources due to
#COVID
-19 pandemic.
Invitamos a todos los pacientes con cáncer de pulmón con mutación de ALK de México y de Hispanoamérica, a que hablemos de la enfermedad y las opciones de tratamiento, así como compartir testimonios y resolver dudas, el evento sera presencial en el
@incanMX
y virtual el 1 de
thoracic oncology unit of
@incan
cares for patients in a multidisciplinary way with oncology, surgery, radiotherapy, pulmonology, rehabilitation, psychology, smoking cessation clinic, screening and translational medicine lab, with or without pandemic, cancer treatment can't stop
Our paper shows that NSCLC patients with oligometastatic disease treated locoregionally in the primary tumor and metastases after a systemic treatment may have a survival greater than 60% at 3 years, particularly those who achieve complete response with pet.
@AndresFCardonaZ
We had the honor to comment on EP versus topotecan (T) as 2nd-line in sensitive relapsed SCLC in
@TheLancetOncol
. PFS was longer in EP than T group (4.7 vs 2.7m 0.004). EP rechallenge can be a reasonable 2nd Ch option. What´s the role of Lurbinectedin in this patient setting?
We publish an update on the multidisciplinary management of TKI-induced diarrhea, a problem that affects the patient's quality of life, even in grade 1 due to long-term treatment
@incanMX
@UToracica
@JennyTurcott
@AndresFCardonaZ
We found a significant benefit of metformin plus TKI EGFR only in overweight patients with lung adenocarcinoma, currently, we are recruiting patients in a phase III study (MET-LUNG) to confirm our findings.
@JAMAOnc
@incanMX
#lungcancer
#egfr
En la Reunión de Best of Asco 2020 se dará reconocimiento a tres médicos que han impulsado la Oncología en México, Dra. Cervantes
@ISSSTE_mx
, Dr. Quintero
@HGM_OD
y el Dr. Lara del
@incanMX
. Muy merecido premio
@SMEOMX
,
@mtzsaid
Our paper in EurJCancer
@OncologyAdvance
we show that MEOX2/GLI1 promotes resistance to EGFR-TKI in lung cancer cells, modulating the activation of the AKT ERK signaling pathway. MEOX2/GLI1 is a potential therapeutic target in resistance to TKI / EGFR 10.1016 / j.ejca.2021.10.032
El
@incanMX
tiene la productividad científica (artículos grupo III al VII) más alta por investigador dentro de los institutos
@CCINSHAE_mx
(2.38 [133/56 investigadores] y el porcentaje más alto (90% junto con
@INMEGEN
) en revisas de alto impacto, orgulloso de pertenecer al Incan
We’re excited to share some
#realworlddata
regarding use of
#Brigatinib
in pts with
#ALK
(+) advaced
#NSCLC
undergoing second or further line of therapy. With a 12-mo OS if 80% and a consistent safety profile w/previous trials,
#brigatinib
is an effective scheme in this population
Several studies have presented evidence that TB could be associated with the development of LC. Our study shows that in lung adeno, a large proportion of tumor samples have MTb DNA seq IS6110
El Dr. Eucario Leon, coordinador de oncología del
@incmnszmx
, recibió el premio a trayectoria en oncología Aida WEISS de la UNAM, el Dr León ha tenido gran influencia en muchos de los oncólogos de nuestro país, muy merecido premio
@EnriqueSoto8
@yaninchavarri
@Dra_CVillarreal
In our study, we found a high prevalence (Of 201 patients, 43 [21.4%]) of Pathogenic or likely pathogenic germline variants (PGVs) in lung adenocarcinoma patients with a family history of LC, young-onset presentation, history of never/light smoking, or actionable genomic
Gracias al Comité de cáncer de pulmón del consejo de salubridad, el protocolo está listo, importante dar el seguimiento para su aprobación y financiamiento en el seguro popular
Our study reports the first in-human use of a 64CuCl2 PET, in the primary staging of patient’s with NSCLC. Results show that 64CuCl2PET had a good ability to detect lesions, opening the possibility to differenciate among pts who might benefit from platinum-based CT.
@incanMX
In our article , we found that PD-L1 expression (TPS >1%) is present in 42.4% of samples from patients with advanced mesothelioma. Additionally, we show that PD-L1 addition to CALGB scores represents an independent prognostic factor for shorter PFS and OS.
Proud to participate in this study and to be part of this academic group, results that partly explain the differences in the profiles of mutations in lung cancer between populations
STK11/LKB1 m are associated with poor prognosis particularly with IO in lung adeno, we found loss of LKB1 immunohistochemical protein expression in 66.3%, it was associated with short outcome in EGFRwt.
@AndresFCardonaZ
@diegoadiazg
@RCatalanMD
Our review discuss the function and genetic alterations of ATM and its role in lung cancer pathogenesis, followed by a perspective highlighting current and potential therapeutic approaches to manage ATM-deficient lung cancers
@juanmanuelhm
@ChristianRolfo
Importante fortalecer los lazos entre España y LATAM para hacer investigación en cáncer de pulmón para mejorar el pronóstico de los pacientes, cambiar la historia de este cáncer, impactar en políticas públicas
@MARIANOPROVENCI
@AndresFCardonaZ
@fcounago
@CLICaP_
@gecp_org
We have just published in
#RedJournal
our randomized phase II study. Nitroglycerin (ngy) plus whole intracranial radiotherapy for brain metastases in nsclc. Results suggest that concurrent NTG and radiotherapy improves iORR and ICPFS.
@incanMX
La academia mexicana de ciencias, L’Oréal y la UNESCO anunciaron el premio para mujeres en la ciencia a la Dra Jenny Turcott, apoyo para realizar investigación de anorexia en pacientes con cancer de pulmón en el
@incanMX
, felicidades,
@lucia_zatarain
@amciencias
,
@JennyTurcott
EL CÁNCER NOS UNE, necesario una ley nacional contra el cáncer en mexico, trabajando de manera conjunta académicos, gobierno a diferentes niveles, instituciones de salud y organizaciones sociales
@incanMX
@amlccorg
@SaludSPPS
@senadomexicano
Patients with cancer appear more vulnerable to SARS-COV-2: a multi-center study during the COVID-19 outbreak, Cancer Discov 2020
Compared with COVID-19 patients without cancer, patients with cancer had higher observed death rates (OR 2.34, 95% CI [1.15, 4.77]; p=0.03)
Long PFS (18.4 months) and high response rate in RET rearrangements positive lung cancer patients treated with selpercatinib. Should it be a first-line standard? Do we need a phase 3 study with the confirmation of these results?
@AndresFCardonaZ
@ChristianRolfo
We are proud to participate in the study TERAVOLT, Thoracic cancers (TC) international COVID-19 collaboration (TERAVOLT): Small-cell lung cancer and other rare thoracic malignancies. SCLC patients showed the highest mortality rate among TC patients.
Pronunciamiento de la
@amciencias
@ANacionalMed
y academia de ingeniería de mexico sobre la acusación de delincuencia organizada de científicos destacados en mx
@incanMX
@agphilloOFICIAL
Los vapeadores o los cigarrillo electrónicos puede contener nicotina y otras sustancias adictivas que pueden causar enfermedades pulmonares, cardiacas y cáncer. Este es un importante mensaje para educar a la población
@MarisolNeumo
@UToracica
In this study conducted in the UK (Lancet Oncol 023-34) additional deaths in lung, breast, colon and esophagus cancer were estimated to be between 3291 and 3621 during the covid-19 pandemic, due to delay in the diagnosis of cancer. It is urgent to prioritize cancer care in Mexico
During the SWOG meeting in Seattle, the Latin American group (Colombia, Chile, Peru, Mexico and Uruguay) presented their participation in clinical studies with the most important cooperative group in the USA, Mariana Chavez, leader of Latam SWOG
@incanMX
@SWOG
@MDAndersonNews
Our study explores B-cell seroconversion following SARS-CoV-2 immunization in healthy individuals and NSCLC patients. A higher percentage of healthy individuals developed more SARS-CoV-2 neutralizing antibodies than NSCLC patients (63% vs. 54.3%; p 0.03). Results showed a
We have just published a review of CD47, a cell surface protein that acts as an inhibitor of phagocytosis. In this way CD47 acts as a "don´t eat me signal" for healthy self-cells; loss of CD47 leads to phagocytosis of aged or damaged cells. J Immunol Res
Good news in the area of thoracic oncology
Positive results from the LAURA Phase III trial showed osimertinib demonstrated a statistically significant and highly clinically meaningful improvement in PFS for patients with unresectable, Stage III EGFRm NSCLC After
In the United Kingdom, the increase in cancer deaths at 5 years after diagnosis is between 4.8% for lung cancer and 16.6% for colorectal cancer and a very significant loss of life years in patients with cancer during the covid-19 pandemic. In Mexico we cannot delay cancer care.
Características de líderes en Latinoamérica, platica del dr Barrios, estos premio noveles tiene pasión, compromiso y responsabilidad social
@AndresFCardonaZ
@BrasilOncologia